TALOPH(600222)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 422,282,414.89, representing a year-on-year increase of 1.52%[5] - The net profit attributable to shareholders of the listed company was CNY 2,329,695.73, showing a significant decrease of 91.33% compared to the same period last year[5] - The basic earnings per share (EPS) was CNY 0.0041, down 91.48% year-on-year[6] - Total revenue for Q1 2022 was CNY 422,282,414.89, a slight increase of 0.78% compared to CNY 415,958,437.10 in Q1 2021[22] - Net profit for Q1 2022 was CNY 2,166,570.19, a significant decrease of 91.86% from CNY 26,632,438.79 in Q1 2021[23] - The company's operating profit for Q1 2022 was CNY 2,976,218.24, down from CNY 30,641,135.93 in Q1 2021, indicating a decline of 90.31%[23] - Basic and diluted earnings per share for Q1 2022 were CNY 0.0041, down from CNY 0.0481 in Q1 2021, a decline of 91.49%[24] - Other comprehensive income for Q1 2022 was negative CNY 4,641,036.70, contrasting with a positive CNY 196,461,366.30 in Q1 2021[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,789,529,131.70, a slight increase of 0.15% from the end of the previous year[6] - The total assets as of Q1 2022 amounted to CNY 3,789,529,131.70, slightly up from CNY 3,783,772,407.22 at the end of Q1 2021[21] - Total liabilities for Q1 2022 were CNY 1,884,367,020.68, down from CNY 2,006,135,829.69 in Q1 2021, a decrease of 6.09%[21] - The company's total equity increased to CNY 1,905,162,111.02 in Q1 2022, compared to CNY 1,777,636,577.53 in Q1 2021, marking an increase of 7.16%[21] Cash Flow - The net cash flow from operating activities was negative at CNY -151,971,688.24, indicating a significant cash outflow[5] - Cash inflow from operating activities for Q1 2022 was 312.19 million in Q1 2021, representing a 16.5% increase[26] - Net cash outflow from operating activities for Q1 2022 was -43.52 million in Q1 2021, indicating a significant decline[27] - Cash inflow from investment activities for Q1 2022 was 162.82 million in Q1 2021, marking a 263.5% rise[27] - Cash inflow from financing activities for Q1 2022 was 165.15 million in Q1 2021, showing a decrease of 38.1%[27] - The ending cash and cash equivalents balance for Q1 2022 was 493.69 million in Q1 2021, indicating a decline of 56.7%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,264[10] - The company’s major shareholder changed to Zhengzhou Tai Rong Industrial Investment Co., Ltd., which acquired 82,441,168 shares, accounting for 14.37% of the total share capital[13] - The company’s board of directors and supervisory board were restructured on February 25, 2022, with a new chairman elected[13] - The company’s repurchase account held 10,846,107 shares, representing 1.89% of the total shares as of the reporting period[12] Expenses and Investments - The decline in net profit was primarily due to the sales restrictions on four categories of drugs, leading to decreased revenue and gross profit[8] - The company faced increased sales expenses as it intensified market promotion for other product lines[8] - Research and development expenses increased to CNY 19,581,712.93 in Q1 2022, compared to CNY 14,409,179.35 in Q1 2021, reflecting a growth of 36.06%[23] - Non-recurring gains and losses amounted to a net loss of CNY -120,616.38 after tax adjustments[8] - The company received financial support of up to 1.2 billion RMB from its indirect controlling shareholder, with the first tranche of 419 million RMB already received[15] - The company’s long-term equity investments stood at 15,473,270.37 RMB as of March 31, 2022, slightly down from 15,724,611.04 RMB at the end of 2021[17] - The company’s total liabilities and equity structure will be impacted by the recent changes in major shareholders and financial support arrangements[13][15]